Fig. 2

DFO preferentially suppresses β-catenin-activated cell proliferation and tumor formation. A–E, Viability of cells treated with DFO at different concentrations for 48 h. 10 hepatic cell lines (A); MHCC97H (B) or SNU398 (C) transfected with control or β-catenin siRNA; and SNU886 (D) or HuH7 (E) transfected with vector or β-catenin^mut plasmid. Protein abundances were analyzed (B, up; C, up; D, left; E, left). F–H, Nude mice subcutaneously inoculated with β-catenin^Δ(ex3)/+ MEFs were administered intraperitoneally with PBS or DFO (400 mg/kg) every other day. Tumor growth was calculated as the mean value in tumor volume (F). Tumor images, tumor weights (G), and body weights (H) were plotted at the end of treatment; n = 6. I–K, Nude mice were subcutaneously inoculated with HuH7 transfected with vector or β-catenin^mut plasmid. These mice were administered intraperitoneally with PBS or DFO (400 mg/kg) every other day. Tumor growth was calculated as the mean value in tumor volumes (I). Tumor images, tumor weights (J), and body weights (K) were plotted at the end of treatment; n = 6. Data were shown as mean ± SD and analysis was performed using t test. *p < 0.05, ***p < 0.001